The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
Open accessThe DOI matches its Crossref record; 143 of the 146 references it cites were found in a registry or an index.
Abstract
The 2016 and 2021 World Health Organization 2021 Classification of central nervous system tumors have resulted in a major improvement in the classification of isocitrate dehydrogenase (IDH)-mutant gliomas. With more effective treatments many patients experience prolonged survival. However, treatment guidelines are often still based on information from historical series comprising both patients with IDH wild-type and IDH-mutant tumors. They provide recommendations for radiotherapy and chemotherapy for so-called high-risk patients, usually based on residual tumor after surgery and age over 40. More up-to-date studies give a better insight into clinical, radiological, and molecular factors associated with the outcome of patients with IDH-mutant glioma. These insights should be used today for risk stratification and for treatment decisions. In many patients with IDH-mutant grades 2 and 3 glioma, if carefully monitored postponing radiotherapy and chemotherapy is safe, and will not jeopardize the overall outcome of patients. With the INDIGO trial showing patient benefit from the IDH inhibitor vorasidenib, there is a sizable population in which it seems reasonable to try this class of agents before recommending radio-chemotherapy with its delayed adverse event profile affecting quality of survival. Ongoing trials should help to further identify the patients that are benefiting from this treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the grading criteria in the current classification schema for oligodendrogliomas continues to predominantly rely upon histopathologic examination; the differentiating criterion between grade 2 and grade 3 oligodendrogliomas are the presence of conspicuous microvascular proliferation and/or 6 mitoses per 10 high-power field [3,4,5,6,7,8,9,10,11].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on RTOG 9802 and EORTC 22033–26033 criteria, our patient is categorized as high-risk on the basis of his age at diagnosis.”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the contrary, he is stratified to a low-risk classification under the EORTC 22844/5 and RTOG 0424 criteria (oligodendroglioma lineage, and absence of pre-operative neurological deficit, unknown preoperative tumor diameter) [10,24,28,32,33,34,35].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The role of age as a prognostic indicator for oligodendrogliomas remains a matter of debate with a historical threshold of ≥ 40 years as the benchmark for high-risk classification in grade 2 gliomas [10].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“10 15 With the increasing use of early maximal safe surgery and radiotherapy followed by alkylating chemotherapy, the nat-ural history of these tumors can no longer be studied.”
BackgroundSelf-citationThe 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273 · cited 2×
“68 77 A study based on selected patient cohorts included in EORTC trials 26053 (CATNON) and 22033-26033 reported that ≤ 2 mitoses per 10 microscopic HPF was significantly associated with longer PFS in patients with IDHmt astrocytoma without homozygous CDKN2A/CDKN2B deletion.”
BackgroundSelf-citationDNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033 · cited 1×
“135 The prognostic significance of this distinction was confirmed in independent datasets, both in in grade 3 and in grades 2–4 astrocytomas.”
BackgroundSelf-citationCeccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,189 · cited 2×
“98 Patients with an initial diagnosis of G-CIMP-low tumors exhibited shorter overall survival compared to those with G-CIMP-high, accompanied by notable alterations in cell cycle pathways, CDKN2A/B deletions, and MET amplifications.”
BackgroundSelf-citationEANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationZhao, Z., Zhang, K.-N., Wang, Q., Li, G., Zeng, F., Zhang, Y., Wu, F., Chai, R., Wang, Z., Zhang, C., et al. (2021) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.10.005 · Cited by 1,098
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064 · cited 1×
“2,11,15 Two studies addressed immediate postoperative treatment versus delayed treatment and found no effect on survival; but here also patient selection appears to have played a major role in the choice for early treatment.”
BackgroundPrognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304194 · Cited by 814
Self-citationTransformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727 · cited 1×
“141,142 Multiple IDH inhibitors have been developed, some specific for mutant IDH1, while others inhibit both mutant IDH1 and IDH2.”
BackgroundMechanisms and therapeutic implications of hypermutation in gliomas
Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortes-Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 677 · cited 2×
“57 57–59 However, as a word of caution, studies have shown that 25%–30% of patients with IDH-mutant gliomas may develop pseudoprogression following radiotherapy.”
BackgroundMethodSelf-citationMolinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., Shai, A., Lafontaine, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6143 · Cited by 631 · cited 1×
“37,38,41 A small single-institutional study on patients with grade 3 IDH-mutant and 1p/19q-codeleted oligodendroglioma failed to detect an association between the extent of resection and survival.”
Backgroundvan den Bent, M. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0725-7 · Cited by 577
Capper, D., Stichel, D., Sahm, F., Jones, D. T. W., Schrimpf, D., Sill, M., Schmid, S., Hovestadt, V., Reuss, D. E., Koelsche, C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1879-y · Cited by 567 · cited 1×
“134 This “Heidelberg methylation classifier” distinguishes an “Astrocytoma, IDH-mutant; high grade” class (A IDH HG) from an “Astrocytoma, IDH-mutant; lower grade” (A IDH) class, with different clinical outcomes.”
BackgroundSelf-citationLongitudinal molecular trajectories of diffuse glioma in adults
Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro, K. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1775-1 · Cited by 561 · cited 1×
“24,73,75,103,104 High mutational burden has been described in recurrent IDHmt astrocytoma in particular following treatment with temozolomide due to defects in mismatch repair genes, which is associated with enhancing recurrences and a worse prognosis and development of discontiguous disease.”
BackgroundSelf-citationMutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553 · cited 1×
“110,111 CIC inactivation has been shown to cooperate with mutant IDH in fostering increased production of 2-hydroxyglutatrate (2-HG), and has been linked to aberrant activation of MAPK/Ras signaling.”
BackgroundcIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Brat, D. J., Aldape, K., Colman, H., Figrarella-Branger, D., Fuller, G. N., Giannini, C., Holland, E. C., Jenkins, R. B., Kleinschmidt-DeMasters, B., Komori, T., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02127-9 · Cited by 520
Self-citationNovel, improved grading system(s) for IDH-mutant astrocytic gliomas
Shirahata, M., Ono, T., Stichel, D., Schrimpf, D., Reuss, D. E., Sahm, F., Koelsche, C., Wefers, A., Reinhardt, A., Huang, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1849-4 · Cited by 457 · cited 5×
“75,95 Both mutual exclusivity with homozygous deletion of 3).”
BackgroundInfluentialSelf-citationBeiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not159 · Cited by 456 · cited 1×
“37,38,41 A small single-institutional study on patients with grade 3 IDH-mutant and 1p/19q-codeleted oligodendroglioma failed to detect an association between the extent of resection and survival.”
BackgroundSelf-citationOlar, A., Wani, K. M., Alfaro-Munoz, K. D., Heathcock, L. E., van Thuijl, H. F., Gilbert, M. R., Armstrong, T. S., Sulman, E. P., Cahill, D. P., Vera-Bolanos, E., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1398-z · Cited by 354 · cited 2×
“17,27,29,30 One study of grade 3 astrocytoma patients found an association only in patients over 60 years, while another study reported a modest association in patients over 50 years.”
BackgroundSelf-citationReuss, D. E., Mamatjan, Y., Schrimpf, D., Capper, D., Hovestadt, V., Kratz, A., Sahm, F., Koelsche, C., Korshunov, A., Olar, A., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1438-8 · Cited by 348 · cited 2×
“16 New, contemporary cohort studies on patients with IDH-mutant gliomas are needed on all aspects of diagnosis and treatment to understand the outcome of patients.”
BackgroundSelf-citationWijnenga, M. M. J., French, P. J., Dubbink, H. J., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Smits, M., Gahrmann, R., Rutten, G.-J., Verheul, J. B., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox176 · Cited by 334 · cited 5×
“25,32 The role of supramaximal resection in IDH-mutant glioma remains controversial, due in part to the lack of a reliable method to quantify the extent of resection beyond the T2/FLAIR-hyperintense tumor borders.”
BackgroundMethodInfluentialSelf-citationvan den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clement, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00090-5 · Cited by 330
Self-citationIntegrated genomic characterization of IDH1-mutant glioma malignant progression
Bai, H., Harmancı, A. S., Erson-Omay, E. Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S. B., Sorensen, E. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3457 · Cited by 329 · cited 1×
“130,131 Tumors without malignant progression did not show such large differences, and a third methylation profile “G-CIMP-high at risk to low” subsequently identified patients with an intermediate prognosis.”
BackgroundIvosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Mellinghoff, I. K., Ellingson, B. M., Touat, M., Maher, E., De La Fuente, M. I., Holdhoff, M., Cote, G. M., Burris, H., Janku, F., Young, R. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03327 · Cited by 324
Self-citationPekmezci, M., Rice, T., Molinaro, A. M., Walsh, K. M., Decker, P. A., Hansen, H., Sicotte, H., Kollmeyer, T. M., McCoy, L. S., Sarkar, G., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1690-1 · Cited by 319 · cited 1×
“118 In addition, increased MYC signaling has been found in a clinically more aggressive subgroup of IDHmt and 1p/19q-codeleted oligodendroglioma demonstrating an oligodendrocyte precursor-like gene expression signature, and MYC gain has been shown to be associated with the risk of developing a…”
BackgroundYip, S., Butterfield, Y. S., Morozova, O., Chittaranjan, S., Blough, M. D., An, J., Birol, I., Chesnelong, C., Chiu, R., Chuah, E., et al. (2012) · The Journal of Pathology · doi:10.1002/path.2995 · Cited by 307 · cited 1×
“110,111 CIC inactivation has been shown to cooperate with mutant IDH in fostering increased production of 2-hydroxyglutatrate (2-HG), and has been linked to aberrant activation of MAPK/Ras signaling.”
BackgroundPrognostic relevance of genetic alterations in diffuse lower-grade gliomas
Aoki, K., Nakamura, H., Suzuki, H., Matsuo, K., Kataoka, K., Shimamura, T., Motomura, K., Ohka, F., Shiina, S., Yamamoto, T., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox132 · Cited by 307
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Malta, T. M., de Souza, C. F., Sabedot, T. S., Silva, T. C., Mosella, M. S., Kalkanis, S. N., Snyder, J., Castro, A. V. B., & Noushmehr, H. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox183 · Cited by 302 · cited 1×
“128 Within the IDH-mutant astrocytoma tumor subgroup, 2 major methylation subgroups have been identified by genome-wide DNA methylation profiling: Glioma-CpG Island Methylator Phenotype (G-CIMP)-low and G-CIMP-high, with G-CIMP-low tumors displaying lower levels of genome-wide DNA-methylation…”
BackgroundSelf-citationAppay, R., Dehais, C., Maurage, C.-A., Alentorn, A., Carpentier, C., Colin, C., Ducray, F., Escande, F., Idbaih, A., Kamoun, A., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz124 · Cited by 278 · cited 4×
“28 Another study that investigated IDHmt and 1p/19q-codeleted oligodendroglioma patients over 60 years found no difference in comparison with patients under 60 years.”
BackgroundResultInfluentialSelf-citationMellinghoff, I. K., Penas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Janku, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0611 · Cited by 271
Self-citationMazor, T., Pankov, A., Johnson, B. E., Hong, C., Hamilton, E. G., Bell, R. J. A., Smirnov, I. V., Reis, G. F., Phillips, J. J., Barnes, M. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.012 · Cited by 258 · cited 1×
“130,131 Tumors without malignant progression did not show such large differences, and a third methylation profile “G-CIMP-high at risk to low” subsequently identified patients with an intermediate prognosis.”
BackgroundPallud, J., Mandonnet, E., Duffau, H., Kujas, M., Guillevin, R., Galanaud, D., Taillandier, L., & Capelle, L. (2006) · Annals of Neurology · doi:10.1002/ana.20946 · Cited by 250 · cited 1×
“3,8,9 The historical studies that identified these factors included both IDHmt and IDH wild-type (IDHwt) tumors, and it cannot be assumed that they remain valid for determining prognosis in IDH-mutant glioma patients following the introduction of the WHO 2016 classification.”
BackgroundSelf-citationMellinghoff, I. K., Lu, M., Wen, P. Y., Taylor, J. W., Maher, E. A., Arrillaga-Romany, I., Peters, K. B., Ellingson, B. M., Rosenblum, M. K., Chun, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02141-2 · Cited by 241
Self-citationOligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
Giannini, C., Scheithauer, B. W., Weaver, A. L., Burger, P. C., Kros, J. M., Mork, S., Graeber, M. B., Bauserman, S., Buckner, J. C., Burton, J., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.3.248 · Cited by 219 · cited 1×
“80 However, the 2021 WHO CNS classification emphasized that “data defining a clear cutoff point for a mitotic count that distinguish CNS WHO grade 2 from CNS WHO grade 3 of IDHmt 1p/19q co-deleted oligodendroglioma are not available.””
BackgroundBell, E. H., Zhang, P., Shaw, E. G., Buckner, J. C., Barger, G. R., Bullard, D. E., Mehta, M. P., Gilbert, M. R., Brown, P. D., Stelzer, K. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02983 · Cited by 219
Self-citationEvidence-based recommendations on categories for extent of resection in diffuse glioma
Karschnia, P., Vogelbaum, M. A., van den Bent, M., Cahill, D. P., Bello, L., Narita, Y., Berger, M. S., Weller, M., & Tonn, J.-C. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.002 · Cited by 212
Self-citationMolenaar, R. J., Verbaan, D., Lamba, S., Zanon, C., Jeuken, J. W. M., Boots-Sprenger, S. H. E., Wesseling, P., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou005 · Cited by 207 · cited 1×
“137,138 In a study comparing radiotherapy to temozolomide chemotherapy in grade 2 gliomas MGMT status appeared to be associated with a longer PFS in astrocytoma IDHmt after temozolomide treatment, but whether MGMT status has an effect on survival in grade 2 astrocytoma IDHmt is unclear.”
BackgroundCellular Proliferation in Pilocytic and Diffuse Astrocytomas
Giannini, C., Scheithauer, B. W., Burger, P. C., Christensen, M. R., Wollan, P. C., Sebo, T. J., Forsyth, P. A., & Hayostek, C. J. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199901000-00006 · Cited by 185
de Souza, C. F., Sabedot, T. S., Malta, T. M., Stetson, L., Morozova, O., Sokolov, A., Laird, P. W., Wiznerowicz, M., Iavarone, A., Snyder, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.107 · Cited by 177 · cited 1×
“132,133 In parallel to these findings, a German group developed a classifier to aid the typing of brain tumors.”
BackgroundSelf-citationHervey-Jumper, S. L., Zhang, Y., Phillips, J. J., Morshed, R. A., Young, J. S., McCoy, L., Lafontaine, M., Luks, T., Ammanuel, S., Kakaizada, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02929 · Cited by 175 · cited 5×
“25,32 The role of supramaximal resection in IDH-mutant glioma remains controversial, due in part to the lack of a reliable method to quantify the extent of resection beyond the T2/FLAIR-hyperintense tumor borders.”
BackgroundMethodInfluentialKawaguchi, T., Sonoda, Y., Shibahara, I., Saito, R., Kanamori, M., Kumabe, T., & Tominaga, T. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2201-2 · Cited by 166 · cited 2×
“18,25,32,35 37 These studies show that preoperative tumor size was prognostic in both IDHmt astrocytoma and IDHmt and 1p/19q-codeleted oligodendroglioma patients, whereas residual tumor volume was predominantly associated with prognosis in IDHmt astrocytoma patients.”
BackgroundKocakavuk, E., Anderson, K. J., Varn, F. S., Johnson, K. C., Amin, S. B., Sulman, E. P., Lolkema, M. P., Barthel, F. P., & Verhaak, R. G. W. (2021) · Nature Genetics · doi:10.1038/s41588-021-00874-3 · Cited by 166
Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov182 · Cited by 163 · cited 1×
“20,108,114,115 Although FUBP1 is frequently mutated in IDH-mutant and 1p/19q-codeleted oligodendroglioma, there is no clear association with survival.”
BackgroundSelf-citationJonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0032 · Cited by 157 · cited 1×
“97,142 Despite this, a number of patients with grade 3 IDH-mutant gliomas appear to have benefited from therapy with IDH inhibitors, challenging the perception that IDH inhibitors would be efficacious only in grade 2 non-enhancing IDH-mutant gliomas.”
BackgroundSelf-citationYu, Y., Villanueva-Meyer, J. E., Grimmer, M., Hilz, S., Solomon, D. A., Choi, S., Wahl, M. T., Mazor, T., Hong, C., Shai, A., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab081 · Cited by 133 · cited 3×
“57 57–59 However, as a word of caution, studies have shown that 25%–30% of patients with IDH-mutant gliomas may develop pseudoprogression following radiotherapy.”
BackgroundMethodYang, R. R., Shi, Z., Zhang, Z., Chan, A. K., Aibaidula, A., Wang, W., Kwan, J. S. H., Poon, W. S., Chen, H., Li, W., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12801 · Cited by 127 · cited 2×
“68 77 A study based on selected patient cohorts included in EORTC trials 26053 (CATNON) and 22033-26033 reported that ≤ 2 mitoses per 10 microscopic HPF was significantly associated with longer PFS in patients with IDHmt astrocytoma without homozygous CDKN2A/CDKN2B deletion.”
BackgroundMethodCimino, P. J., Zager, M., McFerrin, L., Wirsching, H.-G., Bolouri, H., Hentschel, B., von Deimling, A., Jones, D., Reifenberger, G., Weller, M., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0443-7 · Cited by 126 · cited 2×
“76,94 Homozygous deletion of RB1 was strongly associated with inferior overall survival among IDH-mutant astrocytomas on univariate analysis.”
BackgroundSelf-citationMultigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma
Hu, X., Martínez-Ledesma, E., Zheng, S., Kim, H., Barthel, F. P., Jiang, T., Hess, K. R., & Verhaak, R. G. W. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now285 · Cited by 116 · cited 1×
“126 A more recent study based on TCGA datasets from 137 oligodendroglioma patients and 2 independent validation cohorts of 218 patients reported on gene expression-based distinction of 2 prognostically distinct subtypes of oligo-dendroglioma, IDH-mutant and 1p/19q-codeleted.”
MethodJuratli, T. A., Tummala, S. S., Riedl, A., Daubner, D., Hennig, S., Penson, T., Zolal, A., Thiede, C., Schackert, G., Krex, D., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03034-6 · Cited by 116 · cited 1×
“52,53 In 53–55 Still, on initial brain MRI only 60% of grade 3 IDH-mutant astrocytomas showed patchy and faint enhancement, whereas 20% to 50% of grade 2 IDH-mutant astrocytomas showed some enhancement.”
BackgroundDonahue, B., Scott, C., Nelson, J. S., Rotman, M., Murray, K. J., Nelson, D. F., Banker, F. L., Earle, J. D., Fischbach, J. A., Asbell, S. O., et al. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00126-0 · Cited by 111
C IC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas
Gleize, V., Alentorn, A., de Kérillis, L. C., Labussière, M., Nadaradjane, A. A., Mundwiller, E., Ottolenghi, C., Mangesius, S., Rahimian, A., Ducray, F., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24443 · Cited by 109 · cited 1×
“20,108,114,115 Although FUBP1 is frequently mutated in IDH-mutant and 1p/19q-codeleted oligodendroglioma, there is no clear association with survival.”
BackgroundSelf-citationOstrom, Q. T., Shoaf, M. L., Cioffi, G., Waite, K. A., Kruchko, C., Wen, P. Y., Brat, D. J., Barnholtz‐Sloan, J. S., & Iorgulescu, J. B. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac198 · Cited by 108
Self-citationKamoun, A., Idbaih, A., Dehais, C., Elarouci, N., Carpentier, C., Letouzé, E., Colin, C., Mokhtari, K., Jouvet, A., Uro-Coste, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms11263 · Cited by 104 · cited 1×
“120 Among these, the oligo-dendrocyte precursor cell-like subgroup showed aberrant MYC activation and significantly worse outcomes independently of histological grade.”
BackgroundSelf-citationRapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Johannessen, T.-C. A., Mukherjee, J., Viswanath, P., Ohba, S., Ronen, S. M., Bjerkvig, R., & Pieper, R. O. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0141 · Cited by 103 · cited 1×
“97,142 Despite this, a number of patients with grade 3 IDH-mutant gliomas appear to have benefited from therapy with IDH inhibitors, challenging the perception that IDH inhibitors would be efficacious only in grade 2 non-enhancing IDH-mutant gliomas.”
BackgroundIntegrated molecular characterization of IDH ‐mutant glioblastomas
Korshunov, A., Casalini, B., Chávez, L., Hielscher, T., Sill, M., Ryzhova, M. V., Sharma, T. S., Schrimpf, D., Stichel, D., Capper, D., et al. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12523 · Cited by 103 · cited 2×
“90,92,93,100 99, 101,”
BackgroundSelf-citationBrasil Caseiras, G., Ciccarelli, O., Altmann, D. R., Benton, C. E., Tozer, D. J., Tofts, P. S., Yousry, T. A., Rees, J., Waldman, A. D., & Jäger, H. R. (2009) · Radiology · doi:10.1148/radiol.2532081623 · Cited by 100 · cited 1×
“3,8,9 The historical studies that identified these factors included both IDHmt and IDH wild-type (IDHwt) tumors, and it cannot be assumed that they remain valid for determining prognosis in IDH-mutant glioma patients following the introduction of the WHO 2016 classification.”
BackgroundLassman, A. B., Hoang-Xuan, K., Polley, M.-Y. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., Taphoorn, M. J. B., Souhami, L., Dinjens, W. N. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02543 · Cited by 98 · cited 4×
“2,11,15 Two studies addressed immediate postoperative treatment versus delayed treatment and found no effect on survival; but here also patient selection appears to have played a major role in the choice for early treatment.”
BackgroundInfluentialSelf-citationMathur, R., Zhang, Y., Grimmer, M., Hong, C., Zhang, M., Bollam, S., Petrecca, K., Clarke, J. L., Berger, M. S., Phillips, J. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa059 · Cited by 94 · cited 1×
“140 To conclude, MGMT promoter assessment is not useful in oligodendroglioma IDHmt and 1p/19q codeleted, its clinical value in IDHmt astrocytoma remains to be demonstrated and is most likely less relevant than CIMP status.”
BackgroundNatsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93
Bady, P., Kurscheid, S., Delorenzi, M., Gorlia, T., van den Bent, M. J., Hoang‐Xuan, K., Vauléon, É., Gijtenbeek, A., Enting, R. H., Thiessen, B. A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1810-6 · Cited by 91 · cited 1×
“136 In grade 4 astrocytoma IDHmt, MGMT methylation status was associated with improved outcome but in the CATNON trial on anaplastic astrocytoma IDHmt, it failed to predict outcome to the addition of temozolomide to radiotherapy.”
BackgroundSelf-citationde la Fuente, M. I., Colman, H., Rosenthal, M. A., Tine, B. A. V., Levacic, D., Walbert, T., Gan, H. K., Vieito, M., Milhem, M. M., Lipford, K., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac139 · Cited by 91
Kavouridis, V. K., Boaro, A., Dorr, J., Cho, E. Y., Iorgulescu, J. B., Reardon, D. A., Arnaout, O. M., & Smith, T. R. (2019) · Journal of neurosurgery · doi:10.3171/2019.6.jns19972 · Cited by 86 · cited 2×
“18,25,32,35 37 These studies show that preoperative tumor size was prognostic in both IDHmt astrocytoma and IDHmt and 1p/19q-codeleted oligodendroglioma patients, whereas residual tumor volume was predominantly associated with prognosis in IDHmt astrocytoma patients.”
BackgroundChang, S. M., Zhang, J., Cairncross, J. G., Gilbert, M. R., Bahary, J.-P., Dolinskas, C. A., Chakravarti, A., Aldape, K., Bell, E. H., Schiff, D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now236 · Cited by 78
Self-citationWick, A., Bähr, O., Schüler, M., Rohrberg, K. S., Chawla, S. P., Jankú, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4256 · Cited by 75 · cited 1×
“146 At advanced stages, tumors can acquire additional genomic alterations that can bypass the need for the mutant IDH enzyme to maintain gliomagenesis and the IDH mutation can even be lost due to copy number alterations.”
BackgroundOligosarcomas, IDH-mutant are distinct and aggressive
Suwala, A. K., Felix, M., Friedel, D., Stichel, D., Schrimpf, D., Hinz, F. E., Hewer, E., Schweizer, L., Dohmen, H., Pohl, U., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02395-z · Cited by 72 · cited 1×
“109 Apart from this rare subgroup, studies have reported that copy number burden was associated with a less favorable outcome in patients with IDH-mutant and 1p/19q-codeleted oligodendroglioma.”
BackgroundSelf-citationReyes-Botero, G., Dehais, C., Idbaih, A., Martin-Duverneuil, N., Lahutte, M., Carpentier, C., Letouzé, E., Chinot, O., Loiseau, H., Honnorat, J., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not235 · Cited by 69 · cited 2×
“28,50,91 In addition, CDKN2A/B homozygous deletions are frequent in the recently identified aggressive oligosarcoma subgroup.”
BackgroundSelf-citationSamuels, B. L., Herndon, J. E., Harmon, D. C., Carey, R. W., Aisner, J., Corson, J. M., Suzuki, Y., Green, M. R., & Vogelzang, N. J. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8<1460::aid-cncr5>3.0.co;2-d · Cited by 69
The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen
Malta, T. M., Sabedot, T. S., Morosini, N. S., Datta, I., Garofano, L., Vallentgoed, W., Varn, F. S., Aldape, K., D'Angelo, F., Bakas, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2093 · Cited by 68 · cited 1×
“132,133 In parallel to these findings, a German group developed a classifier to aid the typing of brain tumors.”
BackgroundSelf-citationImproved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma
Weller, M., Felsberg, J., Hentschel, B., Gramatzki, D., Kubon, N., Wolter, M., Reusche, M., Roth, P., Krex, D., Herrlinger, U., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02662-1 · Cited by 65 · cited 3×
“17,27,29,30 One study of grade 3 astrocytoma patients found an association only in patients over 60 years, while another study reported a modest association in patients over 50 years.”
BackgroundSelf-citationMolecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
Wong, Q. H., Li, K. K., Wang, W., Malta, T. M., Noushmehr, H., Grabovska, Y., Jones, C., Chan, A. K., Kwan, J. S. H., Huang, Q. J., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00778-x · Cited by 64 · cited 2×
“90,92,93,100 99, 101,”
BackgroundSelf-citationFigarella-Branger, D., Mokhtari, K., Dehais, C., Jouvet, A., Uro-Coste, E., Colin, C., Carpentier, C., Forest, F., Maurage, C.-A., Vignaud, J.-M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou047 · Cited by 63 · cited 3×
“57,59 Gene Expression Profiles Microarray-based mRNA expression profiling of 68 IDH-mutant and 1p/19q-codeleted oligodendroglioma treated with radio-+/− chemotherapy revealed an 8-gene signature ( ST3GAL6, QPCT, NQO1, EPHX1, CST3, S100A8, CHI3L1 , and OSBPL3 ) whose overexpression was significantly associated with sho…”
BackgroundSelf-citationTesileanu, C. M. S., van den Bent, M. J., Sanson, M., Wick, W., Brandes, A. A., Clément, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab088 · Cited by 63 · cited 4×
“24,73 Multivariate analysis including grade, homozygous deletion of CDKN2A/B and methylation class showed that the latter 2 were independent prognostic factors, but not histological grade.”
BackgroundInfluentialSelf-citationTesileanu, C. M. S., Vallentgoed, W. R., Sanson, M., Taal, W., Clement, P. M., Wick, W., Brandes, A. A., Baurain, J. F., Chinot, O. L., Wheeler, H., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02291-6 · Cited by 62 · cited 1×
“83”
Self-citationPI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients
Draaisma, K., Wijnenga, M. M. J., Weenink, B., Gao, Y., Smid, M., Robe, P., van den Bent, M. J., & French, P. J. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0265-4 · Cited by 59 · cited 1×
“90,92,93,100 99, 101,”
Self-citationSuchorska, B., Schüller, U., Biczok, A., Lenski, M., Albert, N. L., Giese, A., Kreth, F.-W., Ertl-Wagner, B., Tonn, J.-C., & Ingrisch, M. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.019 · Cited by 59 · cited 2×
“43,47,51 In previously non-enhancing IDH-mutant gliomas, contrast enhancement at progression typically indicates tumor progression to a higher grade of malignancy, associated with more aggressive behavior of the tumor and a worse prognosis.”
BackgroundSelf-citationLeblanc, V., Firme, M. R., Song, J., Chan, S. Y., Lee, M. H., Yip, S. S. F., Chittaranjan, S., & Marra, M. A. (2017) · The Journal of Pathology · doi:10.1002/path.4894 · Cited by 57 · cited 1×
“112,113 Despite some studies reporting an association between CIC mutation or loss of protein expression and outcome, most studies in patients with grade 2 or 3 IDH-mutant and 1p/19q-codeleted oligo-dendroglioma found no prognostic association of CIC mutations.”
BackgroundHuang, R. Y., Young, R. J., Ellingson, B. M., Veeraraghavan, H., Wang, W., Tixier, F., Um, H., Nawaz, R., Luks, T. L., Kim, J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa105 · Cited by 57 · cited 2×
“49,62,63,65,66”
BackgroundSelf-citationMitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma
Yoda, R. A., Marxen, T., Longo, L., Ene, C. I., Wirsching, H., Keene, C. D., Holland, E. C., & Cimino, P. J. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz082 · Cited by 57
Franceschi, E., Tosoni, A., Bartolini, S., Minichillo, S., Mura, A., Asioli, S., Bartolini, D., Gardiman, M. P., Gessi, M., Ghimenton, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.018 · Cited by 57 · cited 1×
“…oligodendroglioma have significantly longer survival compared to patients with grade 3 tumors based on the above histologic criteria 30,74,76 However, recent studies of IDHmt-and 1p/19q-codeleted oligodendroglioma grade 3 indicate that patients with tumors displaying elevated mitotic…”
BackgroundWang, Y. Y., Wang, K., Li, S. W., Wang, J. F., Ma, J., Jiang, T., & Dai, J. P. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4407 · Cited by 56
Cimino, P. J., & Holland, E. C. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz052 · Cited by 56 · cited 1×
“76,94 Homozygous deletion of RB1 was strongly associated with inferior overall survival among IDH-mutant astrocytomas on univariate analysis.”
BackgroundHemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas
Kocakavuk, E., Johnson, K. C., Sabedot, T. S., Reinhardt, H. C., Noushmehr, H., & Verhaak, R. G. W. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad095 · Cited by 54 · cited 1×
“87,88 Hemizygous deletion was identified in 10% of grade 2, 27% of grade 3, and 33% of grade 4 IDHmt astrocytomas.”
BackgroundSelf-citationMutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
Chittaranjan, S., Chan, S. Y., Yang, C. P., Yang, K., Chen, V., Moradian, A., Firme, M. R., Song, J., Go, N. E., Blough, M. D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2401 · Cited by 52 · cited 1×
“112,113 Despite some studies reporting an association between CIC mutation or loss of protein expression and outcome, most studies in patients with grade 2 or 3 IDH-mutant and 1p/19q-codeleted oligo-dendroglioma found no prognostic association of CIC mutations.”
BackgroundHalani, S. H., Yousefi, S., Velazquez Vega, J., Rossi, M. R., Zhao, Z., Amrollahi, F., Holder, C. A., Baxter-Stoltzfus, A., Eschbacher, J., Griffith, B., et al. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0067-9 · Cited by 50 · cited 1×
“20,116,117 The rare absence of TERT promoter mutations in IDH-mutant and 1p/19q-codeleted oligodendro-glioma (occurring in 5% of cases) has been associated with a worse prognosis in one study.”
BackgroundSelf-citationAllelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas
Alentorn, A., Dehais, C., Ducray, F., Carpentier, C., Mokhtari, K., Figarella‐Branger, D., Chinot, O. L., Moyal, E. C., Ramirez, C., Loiseau, H., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002014 · Cited by 49
Self-citationDuregon, E., Bertero, L., Pittaro, A., Soffietti, R., Rudà, R., Trevisan, M., Papotti, M. G., Ventura, L., Senetta, R., & Cassoni, P. (2016) · Oncotarget · doi:10.18632/oncotarget.8498 · Cited by 49 · cited 1×
“27,71 Grading of Oligodendroglioma IDHmt and 1p/19q Codeleted Similar to IDHmt astrocytomas, IDHmt, and 1p/19q-codeleted oligodendroglioma represent a continuous spectrum ranging from indolent and well-differentiated tumors to those that are rapidly progressing.”
BackgroundLi, K. K., Shi, Z., Malta, T. M., Chan, A. K., Cheng, S., Kwan, J. S. H., Yang, R. R., Poon, W. S., Mao, Y. Q., Noushmehr, H., et al. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz015 · Cited by 49 · cited 1×
“90,98,104,129 The recently described LINE-1 methylation sequencing can be used as proxy for genome-wide DNA-methylation levels of a sample, and samples with low LINE-1 methylation levels are associated with grade 4 histology.”
BackgroundSelf-citationLin, Y., Xing, Z., She, D., Yang, X., Zheng, Y., Xiao, Z., Wang, X., & Cao, D. (2017) · Neuroradiology · doi:10.1007/s00234-017-1839-6 · Cited by 47 · cited 1×
“47,48 Neo-angiogenesis and mitotic counts were independently associated with TGRs (TGR) ≥ 8 mm/year.”
Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV foci
Darlix, A., Rigau, V., Fraisse, J., Gozé, C., Fabbro, M., & Duffau, H. (2020) · Neurology · doi:10.1212/wnl.0000000000008877 · Cited by 44 · cited 1×
“34 Codeletion status, pre-and postoperative volume, and TGR were associated with the time to the next treatment.”
BackgroundWHO Grade Loses Its Prognostic Value in Molecularly Defined Diffuse Lower-Grade Gliomas
Carstam, L., Corell, A., Smits, A., Dénes, A., Barchéus, H., Modin, K., Sjögren, H., Vega, S. F., Bontell, T. O., Carén, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.803975 · Cited by 42 · cited 2×
“17,18,25 With respect to postoperative treatments, several papers reported unfavorable outcomes after adjuvant treat-ment (be it radiotherapy, chemotherapy, or both).”
BackgroundBhatia, A., Moreno, R., Reiner, A. S., Nandakumar, S., Walch, H. S., Thomas, T. M., Nicklin, P. J., Choi, Y., Skakodub, A., Malani, R., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1180 · Cited by 42 · cited 2×
“49,62,63,65,66”
BackgroundSelf-citationCastet, F., Alanya, E., Vidal, N., Izquierdo, C., Mesía, C., Ducray, F., Gil‐Gil, M., & Bruna, J. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03183-2 · Cited by 41
Self-citationIdentifying predictors of glioma evolution from longitudinal sequencing
Mu, Q., Chai, R., Pang, B., Yang, Y., Liu, H., Zhao, Z., Bao, Z., Song, D., Zhu, Z., Yan, M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4181 · Cited by 39 · cited 1×
“119,120 PTEN alterations have been associated with shorter survival of patients with grade 2 IDHmt and 1p/19q-codeleted oligo-dendroglioma in one study.”
BackgroundTumor growth dynamics in serially-imaged low-grade glioma patients
Gui, C., Kosteniuk, S., Lau, J. C., & Megyesi, J. F. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2857-x · Cited by 36 · cited 1×
“64 Growth was slower in IDH-mutant and 1p/19q-codeleted oligodendro-glioma than in IDHmt astrocytomas, and was also slower in grade 2 IDH-mutant and 1p/19q-oligodendroglioma codeleted than in grade 3 oligodendroglioma, IDH-mutant and 1p/19q-codeleted.”
BackgroundYamauchi, T., Ohno, M., Matsushita, Y., Takahashi, M., Miyakita, Y., Kitagawa, Y., Kondo, E., Tsushita, N., Satomi, K., Yoshida, A., et al. (2018) · Brain Tumor Pathology · doi:10.1007/s10014-018-0321-4 · Cited by 35
Higher-Order Surgical Questions for Diffuse Low-Grade Gliomas
Duffau, H. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.08.009 · Cited by 35
Tesileanu, C. M. S., Vallentgoed, W., French, P. J., & van den Bent, M. J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.016 · Cited by 35 · cited 1×
“86 However, the presence of hemizygous deletion of CDKN2A/B was also shown to be a marker of less favorable outcome prognosis in patients with IDH-mutant astrocytomas when compared to patients with CDKN2A/B non-deleted tumors.”
ResultSelf-citationPark, Y. W., Park, K. S., Park, J. E., Ahn, S. S., Park, I., Kim, H. S., Chang, J. H., Lee, S., & Kim, S. H. (2023) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0732 · Cited by 34 · cited 2×
“56 Nodular and ring enhancement patterns on contrast-enhanced MRI have also been reported in grade 3 IDH-mutant astrocytomas, and were associated with worse outcomes.”
BackgroundWijnenga, M. M. J., French, P. J., Dubbink, H. J., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Fleischeuer, R. E. M., Dirven, C. M. F., Vincent, A. J. P. E., & van den Bent, M. J. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2867-8 · Cited by 33 · cited 2×
“108 This is despite the mutation being subclonal (similar to CIC mutations) which suggests selection for FUBP1 mutant clones during tumor evolution.”
BackgroundSelf-citationPaľa, A., Coburger, J., Scherer, M., Ahmeti, H., Roder, C., Gessler, F. A., Jungk, C., Scheuerle, A., Senft, C., Tatagiba, M. S., et al. (2019) · Journal of neurosurgery · doi:10.3171/2019.4.jns183395 · Cited by 33 · cited 2×
“17,21,22,26,32,33 A series on patients with grades 3 and 4 tumors reported improved outcomes if postoperative treatment had been given.”
BackgroundFigarella-Branger, D. F., Mokhtari, K., Dehais, C., Carpentier, C., Colin, C., Jouvet, A., Uro‐Coste, E., Forest, F., Maurage, C., Vignaud, J.-M., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now085 · Cited by 32 · cited 1×
“81,82 This suggests that elevated mitotic activity alone is not a strong prognostic marker for aggressive clinical behavior in this tumor type.”
BackgroundSelf-citationJoyner, D., Garrett, J., Batchala, P. P., Rama, B., Ravicz, J. R., Patrie, J. T., Lopes, M.-B., Fadul, C. E., Schiff, D., Jain, R., et al. (2022) · Neuroradiology · doi:10.1007/s00234-022-03038-0 · Cited by 32 · cited 4×
“43,47,51 In previously non-enhancing IDH-mutant gliomas, contrast enhancement at progression typically indicates tumor progression to a higher grade of malignancy, associated with more aggressive behavior of the tumor and a worse prognosis.”
BackgroundInfluentialLong-term follow up of patients with WHO grade 2 oligodendroglioma
Carstam, L., Latini, F., Solheim, O., Bartek, J., Pedersen, L. K., Zetterling, M., Beniaminov, S., Sjåvik, K., Ryttlefors, M., Jensdottir, M., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04368-6 · Cited by 31 · cited 3×
“11,19,20 A study on grade 3 and 4 IDH-mutant glioma found a more pronounced association with age in grade 3 oligodendroglioma patients, using the observed median (49.5 years).”
BackgroundInfluentialKros, J. M., Rushing, E. J., Uwimana, A. L., Hernández‐Laín, A., Michotte, A., Al-Hussaini, M. A., Bielle, F., Mawrin, C., Marucci, G., Tesileanu, C. M. S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac282 · Cited by 30 · cited 1×
“78 A population-based report on clinical outcomes of IDHmt astrocytoma patients who were diagnosed according to the 2016 WHO classification of CNS tumors demonstrated that patients with WHO grade 2 IDH-mutant astrocytomas had a modest, but statistically significant, higher survival rate at 1 year…”
MethodSelf-citationLee, K.-H., Kim, S., Kim, E. E., Shim, Y., Won, J., Park, C., Choi, S. H., Yun, H., Lee, H., & Park, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-32153-y · Cited by 28 · cited 1×
“MYCN amplification has been shown to be associated with shorter survival in patients with IDH-mutant astrocytomas (grades 2–4) 75,93,96 The frequency of MYCN -amplification increases with WHO 2016 tumor grade (Table 3), and was relatively high (8%–12”
BackgroundMitosis identification in diffuse gliomas: implications for tumor grading.
Coons, S. W., & Pearl, D. K. (1998) · PubMed · Cited by 27
Hickman, R. A., Gedvilaite, E., Ptashkin, R. N., Reiner, A. S., Cimera, R., Nandakumar, S., Price, A., Vanderbilt, C., Fahy, T., Young, R. J., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02639-0 · Cited by 27 · cited 1×
“88,90 Other studies have concluded that CDK4 amplification, when considered by itself, was not associated with poor prognosis on univariate analysis.”
BackgroundSelf-citationMitosis identification in diffuse gliomas
Coons, S. W., & Pearl, D. K. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8<1550::aid-cncr17>3.0.co;2-3 · Cited by 27
Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors
Chen, H., Thomas, C., Munoz, F. A., Alexandrescu, S., Horbinski, C., Olar, A., McGuone, D., Camelo-Piragua, S. I., Wang, L., Pentsova, E. I., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz098 · Cited by 26 · cited 1×
“121 Chromosomal copy number variations in addition to 1p/19q codeletion increase significantly from grades 2 to 3 in IDH-mutant and 1p/19q-codeleted oligodendroglioma.”
BackgroundSelf-citationAoki, K., Suzuki, H., Yamamoto, T., Yamamoto, K. N., Maeda, S., Okuno, Y., Ranjit, M., Motomura, K., Ohka, F., Tanahashi, K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0985 · Cited by 26 · cited 1×
“49,62,63,65,66”
Roux, A., Tauziède‐Espariat, A., Zanello, M., Peeters, S., Zah‐Bi, G., Párraga, E., Edjlali, M., Lechapt, E., Shor, N., Bellu, L., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa022 · Cited by 25 · cited 3×
“49,62,63,65,66”
BackgroundSelf-citationTumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
Alghamri, M. S., Thalla, R., Avvari, R., Dabaja, A. A., Taher, A. W., Zhao, L., Ulintz, P., Castro, M. G., & Lowenstein, P. R. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa042 · Cited by 25 · cited 1×
“124 This study found a similar trend when using GLASS data sets from a small cohort of 25 IDHmt and 1p/19q-codeleted oligodendroglioma patients.”
ResultMamatjan, Y., Voisin, M. R., Nassiri, F., de Moraes, F. Y., Bunda, S., So, J., Salih, M., Shirahata, M., Ono, T., Shimizu, H., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad126 · Cited by 25
Self-citationMGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas
Horbinski, C., McCortney, K., & Stupp, R. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab039 · Cited by 24 · cited 1×
“139 In IDH-mutant low-grade gliomas, the MGMT methylation level in the tumor at first resection was associated with a hypermutational status at tumor recurrence after temozolomide treatment.”
BackgroundImmunological profiles of human oligodendrogliomas define two distinct molecular subtypes
Wu, F., Yin, Y., Fan, W.-H., Zhai, Y., Yu, M., Wang, D., Pan, C., Zhao, Z., Li, G., & Zhang, W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104410 · Cited by 24 · cited 1×
“127 The prognostically unfavorable subtype displayed a proliferative phenotype with enrichment of histologically grade 3 tumors and higher mutation frequency in EGFR , MET, and NOTCH1 .”
BackgroundPark, Y. W., Kim, S., Han, K., Ahn, S. S., Moon, J. H., Kim, E. H., Kim, J., Kang, S., Kim, S. H., Lee, S., et al. (2023) · European Radiology · doi:10.1007/s00330-023-10125-0 · Cited by 24 · cited 3×
“17,21,22,26,32,33 A series on patients with grades 3 and 4 tumors reported improved outcomes if postoperative treatment had been given.”
BackgroundTesileanu, C. M. S., Gorlia, T., Golfinopoulos, V., French, P. J., & van den Bent, M. J. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac014 · Cited by 21 · cited 1×
“137,138 In a study comparing radiotherapy to temozolomide chemotherapy in grade 2 gliomas MGMT status appeared to be associated with a longer PFS in astrocytoma IDHmt after temozolomide treatment, but whether MGMT status has an effect on survival in grade 2 astrocytoma IDHmt is unclear.”
BackgroundSelf-citationMair, M. J., Leibetseder, A., Heller, G., Puhr, R., Tomasich, E., Goldberger, S., Hatziioannou, T., Wöhrer, A., Widhalm, G., Dieckmann, K. U., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1133 · Cited by 21 · cited 2×
“17,21 None of the studies that investigated tumor location reported an association with survival.”
BackgroundSelf-citationPrognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes
Darvishi, P., Batchala, P. P., Patrie, J. T., Poisson, L., Lopes, M. B. S., Jain, R., Fadul, C. E., Schiff, D., & Patel, S. H. (2020) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6511 · Cited by 20 · cited 1×
“52,53 In 53–55 Still, on initial brain MRI only 60% of grade 3 IDH-mutant astrocytomas showed patchy and faint enhancement, whereas 20% to 50% of grade 2 IDH-mutant astrocytomas showed some enhancement.”
BackgroundKling, T., Vega, S. F., Suman, M., Dénes, A., Lipatnikova, A., Lagerström, S., Bontell, T. O., Jakola, A. S., & Carén, H. (2024) · Brain Pathology · doi:10.1111/bpa.13233 · Cited by 20 · cited 1×
“24,73,75,103,104 High mutational burden has been described in recurrent IDHmt astrocytoma in particular following treatment with temozolomide due to defects in mismatch repair genes, which is associated with enhancing recurrences and a worse prognosis and development of discontiguous disease.”
BackgroundBush, N. A. O., Young, J. S., Zhang, Y., Ore, C. L. D., Molinaro, A. M., Taylor, J. W., Clarke, J. L., Prados, M. D., Braunstein, S. E., Raleigh, D. R., et al. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03781-z · Cited by 19 · cited 1×
“42”
Jaspers, J. P. M., Taal, W., van Norden, Y., Zindler, J. D., Swaak‐Kragten, A. T., Habraken, S., Hoogeman, M. S., Nout, R. A., van den Bent, M. J., & Romero, A. M. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109674 · Cited by 19 · cited 1×
“60,61”
Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
Weller, J., Katzendobler, S., Blobner, J., Thiele, F., Becker, H., Quach, S., Egensperger, R., Niyazi, M., Suchorska, B., Thon, N., et al. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04128-y · Cited by 17 · cited 1×
“17,21,22,26,32,33 A series on patients with grades 3 and 4 tumors reported improved outcomes if postoperative treatment had been given.”
BackgroundSelf-citationLasocki, A., Buckland, M. E., Molinaro, T., Xie, J., Whittle, J. R., Wei, H., & Gaillard, F. (2023) · Neuroradiology · doi:10.1007/s00234-023-03175-0 · Cited by 16
Leclerc, A., Roux, A., Elia, A., Peeters, S., Aboubakr, O., Bedioui, A., Planet, M., Benzakoun, J., Simboli, G. A., Tauziède‐Espariat, A., et al. (2024) · Neurosurgical FOCUS · doi:10.3171/2023.11.focus23648 · Cited by 15 · cited 2×
“49,62,63,65,66”
MethodSelf-citationYokoda, R. T., Cobb, W. S., Yong, R. L. M., Crary, J. F., Viapiano, M. S., Walker, J. M., Umphlett, M., Tsankova, N. M., & Richardson, T. E. (2023) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlad063 · Cited by 13 · cited 1×
“89 The prognostic role of CDKN2A/B promoter methylation remains unclear.”
BackgroundMinniti, G. C., Paolini, S., Antonelli, M., Gianno, F., Tini, P., Lanzetta, G., Arcella, A., Pietro, R. D., Giraffa, M., Capone, L., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04418-z · Cited by 13 · cited 5×
“17,21 None of the studies that investigated tumor location reported an association with survival.”
BackgroundInfluentialMichaud, K., de Tayrac, M., D’Astous, M., Duval, C., Paquet, C., Samassékou, O., Gould, P. V., & Saïkali, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168728 · Cited by 11
Tran, S., Thomas, A., Aliouat, I., Karachi, C., Lozano-Sánchez, F. A., Mokhtari, K., Dehais, C., Feuvret, L., Carpentier, C., Giry, M., et al. (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12928 · Cited by 11 · cited 2×
“17,27,29,30 One study of grade 3 astrocytoma patients found an association only in patients over 60 years, while another study reported a modest association in patients over 50 years.”
BackgroundSelf-citationWang, K., Wang, Y., Fan, X., Li, Y., Liu, X., Wang, J., Ai, L., Dai, J., & Jiang, T. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2673-8 · Cited by 10 · cited 2×
“43,47,51 In previously non-enhancing IDH-mutant gliomas, contrast enhancement at progression typically indicates tumor progression to a higher grade of malignancy, associated with more aggressive behavior of the tumor and a worse prognosis.”
BackgroundRichardson, T. E., Williams, M. J., Galbraith, K., Mirchia, K., Kumar, V., Xing, C., & Walker, J. M. (2020) · Clinical Neuropathology · doi:10.5414/np301260 · Cited by 10 · cited 1×
“20,122 In addition”
Trong, P. D., Gluszak, M., Reuss, D., von Deimling, A., Wick, A., König, L., Debus, J., Herold‐Mende, C. C., Unterberg, A. W., & Jungk, C. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04230-1 · Cited by 10 · cited 1×
“23,31 Performance status was associated with outcome in some of the cohorts on IDHmt and 1p/19q-codeleted oligo-dendroglioma (either performance status or neurological function) but in only one study on grade 3 IDH-mutant astrocytoma.”
BackgroundDono, A., Alfaro-Munoz, K. D., Yan, Y., Lopez-Garcia, C. A., Soomro, Z., Williford, G. L., Takayasu, T., Robell, L., Majd, N., de Groot, J., et al. (2022) · Neurosurgery · doi:10.1227/neu.0000000000001875 · Cited by 9 · cited 1×
“20,116,117 The rare absence of TERT promoter mutations in IDH-mutant and 1p/19q-codeleted oligodendro-glioma (occurring in 5% of cases) has been associated with a worse prognosis in one study.”
BackgroundTreatment and outcomes of IDH1-mutant gliomas in elderly patients
Giantini-Larsen, A., Abou-Mrad, Z., Yu, K. K. H., Reiner, A. S., Bale, T., Tabar, V. S., & Bander, E. D. (2023) · Journal of neurosurgery · doi:10.3171/2023.6.jns222907 · Cited by 9 · cited 1×
“52,53 In 53–55 Still, on initial brain MRI only 60% of grade 3 IDH-mutant astrocytomas showed patchy and faint enhancement, whereas 20% to 50% of grade 2 IDH-mutant astrocytomas showed some enhancement.”
BackgroundRichardson, T. E., & Walker, J. M. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa083 · Cited by 8 · cited 3×
“MYCN amplification has been shown to be associated with shorter survival in patients with IDH-mutant astrocytomas (grades 2–4) 75,93,96 The frequency of MYCN -amplification increases with WHO 2016 tumor grade (Table 3), and was relatively high (8%–12”
BackgroundMethodRichardson, T. E., & Walker, J. M. (2021) · Clinical Neuropathology · doi:10.5414/np301354 · Cited by 8
Mutational burden and immune recognition of gliomas
Prost, D. M., Bielle, F., Ligon, K. L., & Touat, M. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000787 · Cited by 8
Self-citationCharacteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study
Garnier, L., Vidal, C., Chinot, O. L., Moyal, E. C., Djelad, A., Bronnimann, C., Bekaert, L., Taillandier, L., Frenel, J., Langlois, O., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac023 · Cited by 7 · cited 1×
“20,123 In addition, a study based on TCGA data sets from 169 IDHmt and 1p/19q-codeleted oligodendroglioma patients revealed that high tumor mutational burden, defined by ≥ 0.69 mutations/megabase of DNA, was significantly associated with shorter survival.”
MethodInfluentialSelf-citationMontégut, C., Guillamo, J., Ducray, F., Dehais, C., Moyal, E. C., Desenclos, C., Petit, A., Seizeur, R., Bekaert, L., Gaultier, C., et al. (2022) · Cancers · doi:10.3390/cancers14225509 · Cited by 7 · cited 2×
“23,31 Performance status was associated with outcome in some of the cohorts on IDHmt and 1p/19q-codeleted oligo-dendroglioma (either performance status or neurological function) but in only one study on grade 3 IDH-mutant astrocytoma.”
BackgroundMethodSelf-citationConsidering the extent of resection in diffuse glioma
Cahill, D. P., & Dunn, G. P. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad165 · Cited by 7 · cited 1×
“40 While it remains unclear whether longer observation periods or larger series will reveal a trend towards a survival benefit after supramaximal resection of IDH-mutant and 1p/19q-codeleted oligodendro-glioma, the yet considerable median follow-up over 11.7 years in a recent study supports the…”
BackgroundInfluentialRetrospective examination of pseudoprogression in IDH mutant gliomas
Wetzel, E. A., Farrell, M. J., Eldred, B. S. C., Liu, V., Saha, I., Rinonos, S. Z., Prins, T. J., Li, T., Cao, M., Hegde, J. V., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad028 · Cited by 4 · cited 1×
“60,61”
Self-citationGilhodes, J., Meola, A., Cabarrou, B., Peyraga, G., Dehais, C., Figarella‐Branger, D., Ducray, F., Maurage, C., Loussouarn, D., Uro‐Coste, E., et al. (2023) · Cancers · doi:10.3390/cancers15123067 · Cited by 4 · cited 1×
“…signature ( ST3GAL6, QPCT, NQO1, EPHX1, CST3, S100A8, CHI3L1 , and OSBPL3 ) whose overexpression was significantly associated with shorter PFS. 81,125 Another study reported on a prognostic 35-gene signature that identified high-risk and low-risk subgroups of 1p/19q codeleted glioma patients.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Louis, 2021, The 2021 WHO classification of tumors of the central nervous system: A summary, Neuro-Oncology., 23, 1231, 10.1093/neuonc/noab106 · DOI · Paper page
- Tesileanu, 2021, Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma, Neuro-Oncology., 23, 1547, 10.1093/neuonc/noab088 · DOI
- Appay, 2019, CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas, Neuro Oncol., 21, 1519
- Aoki, 2018, Prognostic relevance of genetic alterations in diffuse lower-grade gliomas, Neuro Oncol., 20, 66, 10.1093/neuonc/nox132 · DOI · Paper page
- Mellinghoff, 2020, Ivosidenib in isocitrate dehydrogenase 1–mutated advanced glioma, J Clin Oncol., 38, 3398, 10.1200/JCO.19.03327 · DOI · Paper page
Cited by
Karschnia, P., Young, J. S., Wijnenga, M. M. J., Sciortino, T., Teske, N., Corell, A., Wagner, A., Youssef, G., Park, Y. W., Häni, L., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00534-0 · Cited by 39
Self-citationThe role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma
de la Fuente, M. I., Touat, M., van den Bent, M. J., Preusser, M., Peters, K. B., Young, R. J., Huang, R. Y., Ellingson, B. M., Capper, D., Phillips, J. J., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae259 · Cited by 31
Self-citationCanonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis
Ghosh, H. S., Patel, R. V., Claus, E. B., Castro, L. N. G., Wen, P. Y., Ligon, K. L., Meredith, D. M., & Bi, W. L. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae258 · Cited by 26
“6 As such, classification schemes which more accurately define patient risk remain a critical component in the ongoing effort to develop targeted therapeutics that improve on current standards of care.”
Self-citationvan den Bent, M. J., Ghisai, S. A., Wick, W., Sanson, M., Brandes, A. A., Clement, P., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00614-x · Cited by 26
Self-citationGhisai, S. A., van Hijfte, L., Vallentgoed, W., Tesileanu, C. M. S., de Heer, I. J., Kros, J. M., Sanson, M., Gorlia, T., Wick, W., Vogelbaum, M. A., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02811-0 · Cited by 22
Self-citation
Metadata
- Authors
- van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., Figarella Branger, D., Huang, R. Y., Weller, M., Mellinghoff, I. K., Cloughsey, T. F., Huse, J. T., Aldape, K., Reifenberger, G., Youssef, G., Karschnia, P., Noushmehr, H., Peters, K. B., Ducray, F., Preusser, M., & Wen, P. Y.
- Affiliations
- Brain Tumor Center at Erasmus MC Cancer Institute , Rotterdam,
- Erasmus MC Cancer Institute (NL)
- Northwestern University (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Memorial Sloan Kettering Cancer Center (US)
- Inserm (FR)
- Department of Neuropathology, University Hospital Medicine and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ) , Heidelberg,
- German Cancer Research Center (DE)
- DFB Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d’Anatomie Pathologique et de Neuropathologie , Marseille,
- University of Zurich (CH)
- Department of Neurology, TC David Geffen School of Medicine at UCLA , Los Angeles ,
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Düsseldorf University Hospital (DE)
- Harvard University (US)
- Henry Ford Hospital (US)
- Duke University (US)
- Inserm U1052, CNRS UMR5286, Université Claude Bernard Lyon , Lyon,
- Medical University of Vienna (AT)
- ORCID
- van den Bent, Martin J
- French, Pim J
- Brat, Daniel
- Tonn, Joerg C
- Touat, Mehdi
- Ellingson, Benjamin M
- Young, Robert J
- Pallud, Johan
- von Deimling, Andreas
- Sahm, Felix
- Figarella Branger, Dominique
- Huang, Raymond Y
- Weller, Michael
- Mellinghoff, Ingo K
- Cloughsey, Tim F
- Huse, Jason T
- Aldape, Kenneth
- Reifenberger, Guido
- Youssef, Gilbert
- Karschnia, Philipp
- Noushmehr, Houtan
- Peters, Katherine B
- Ducray, Francois
- Preusser, Matthias
- Wen, Patrick Y
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-06-24
- Volume
- 26
- Issue
- 10
- Pages
- 1805-1822
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC11449017
- OpenAlex
- W4399973103
- Cited by
- 88
- References
- 146
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 10
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Neuro-Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- HAL AMU (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Michigan State University
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Hospices Civils de Lyon
- Deutschen Konsortium für Translationale Krebsforschung
- Sorbonne Université
- College of Engineering, Michigan State University
- National Cancer Institute (P30CA008748, P50CA211015, R01CA279984, R01CA270027)
- National Institute of Neurological Disorders and Stroke (R35NS105109)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- IDH-mutant glioma, isocitrate dehydrogenase inhibitors, vorasidenib, tumor grade, age, tumor enhancement, extent of resection, risk stratification, radiotherapy, chemotherapy, treatment decision-making, overall survival, quality of survival
- MeSH terms
- Clinical Decision-Making, Age Factors, Brain Neoplasms, Enzyme Inhibitors, Glioma, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
